X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (41479) 41479
Newsletter (240) 240
Magazine Article (97) 97
Newspaper Article (75) 75
Book Chapter (66) 66
Dissertation (9) 9
Book Review (8) 8
Reference (8) 8
Book / eBook (5) 5
Conference Proceeding (5) 5
Transcript (5) 5
Government Document (4) 4
Publication (4) 4
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (32355) 32355
male (20644) 20644
female (19625) 19625
immunosuppressive agents - therapeutic use (16471) 16471
immunosuppressive agents - administration & dosage (16364) 16364
adult (13174) 13174
middle aged (12645) 12645
transplantation (10163) 10163
animals (9634) 9634
treatment outcome (8359) 8359
immunosuppressive agents - adverse effects (8224) 8224
immunosuppressive agents (7548) 7548
immunology (6696) 6696
aged (6333) 6333
surgery (6148) 6148
adolescent (5117) 5117
immunosuppressive agents - pharmacology (4863) 4863
drug therapy, combination (4627) 4627
therapy (4237) 4237
time factors (4178) 4178
cyclosporine (4097) 4097
retrospective studies (4074) 4074
pharmacology & pharmacy (4039) 4039
child (4006) 4006
immunosuppression (3937) 3937
mice (3902) 3902
kidney transplantation (3857) 3857
tacrolimus (3853) 3853
cyclosporine - administration & dosage (3572) 3572
risk factors (3473) 3473
follow-up studies (3372) 3372
rats (3177) 3177
care and treatment (3108) 3108
cyclosporine - therapeutic use (2976) 2976
graft rejection - prevention & control (2971) 2971
tacrolimus - administration & dosage (2935) 2935
health aspects (2895) 2895
immunosuppressive agents - pharmacokinetics (2832) 2832
dose-response relationship, drug (2783) 2783
immunotherapy (2744) 2744
analysis (2722) 2722
young adult (2688) 2688
drug administration schedule (2614) 2614
research (2480) 2480
hematology (2451) 2451
medicine & public health (2420) 2420
drug therapy (2373) 2373
administration, oral (2360) 2360
recipients (2323) 2323
disease (2287) 2287
mycophenolic acid - analogs & derivatives (2243) 2243
prospective studies (2187) 2187
child, preschool (2162) 2162
tacrolimus - therapeutic use (2161) 2161
dermatology (2153) 2153
kidneys (2149) 2149
dosage and administration (2145) 2145
rheumatology (2120) 2120
transplantation, homologous (2113) 2113
oncology (2099) 2099
gastroenterology & hepatology (2070) 2070
patients (1975) 1975
pharmacokinetics (1849) 1849
urology & nephrology (1836) 1836
children (1803) 1803
recurrence (1795) 1795
inflammation (1792) 1792
pediatrics (1791) 1791
medicine, general & internal (1772) 1772
efficacy (1753) 1753
corticosteroids (1683) 1683
kidney transplantation - immunology (1655) 1655
sirolimus - administration & dosage (1649) 1649
cyclophosphamide (1612) 1612
cyclophosphamide - administration & dosage (1610) 1610
prognosis (1588) 1588
antibodies, monoclonal - therapeutic use (1581) 1581
cancer (1564) 1564
liver transplantation (1553) 1553
cyclosporine - adverse effects (1507) 1507
transplants & implants (1492) 1492
diagnosis (1489) 1489
double-blind (1477) 1477
immunosuppressive agents - blood (1477) 1477
liver (1474) 1474
biopsy (1467) 1467
abridged index medicus (1465) 1465
mycophenolate-mofetil (1458) 1458
graft survival (1446) 1446
mycophenolic acid - therapeutic use (1441) 1441
drugs (1440) 1440
expression (1434) 1434
graft rejection - immunology (1421) 1421
severity of illness index (1421) 1421
disease models, animal (1416) 1416
azathioprine (1411) 1411
safety (1409) 1409
clinical trials (1389) 1389
graft rejection (1389) 1389
azathioprine - therapeutic use (1379) 1379
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (39584) 39584
German (816) 816
Japanese (752) 752
French (467) 467
Spanish (291) 291
Russian (254) 254
Chinese (186) 186
Italian (116) 116
Polish (96) 96
Portuguese (83) 83
Hungarian (77) 77
Danish (38) 38
Norwegian (36) 36
Czech (33) 33
Dutch (17) 17
Romanian (17) 17
Swedish (15) 15
Serbian (13) 13
Croatian (12) 12
Finnish (12) 12
Hebrew (10) 10
Lithuanian (9) 9
Bulgarian (8) 8
Turkish (6) 6
Korean (5) 5
Slovak (3) 3
Ukrainian (3) 3
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2007, Volume 357, Issue 25, pp. 2562 - 2575
This study examines the toxicity of immunosuppressive regimens in renal-transplant recipients. A regimen containing mycophenolate mofetil, daclizumab, low-dose... 
MULTICENTER TRIAL | MEDICINE, GENERAL & INTERNAL | CYCLOSPORINE MICROEMULSION | EFFICACY | KIDNEY-TRANSPLANTATION | IMMUNOSUPPRESSION | ALLOGRAFT RECIPIENTS | TACROLIMUS | MYCOPHENOLATE-MOFETIL | SIROLIMUS | NEPHROTOXICITY | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Adrenal Cortex Hormones - therapeutic use | Enzyme Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized | Calcineurin Inhibitors | Treatment Failure | Adult | Diabetes Mellitus - etiology | Female | Drug Therapy, Combination | Mycophenolic Acid - administration & dosage | Immunosuppressive Agents - administration & dosage | Sirolimus - adverse effects | Tacrolimus - administration & dosage | Prednisone - administration & dosage | Glomerular Filtration Rate | Graft Rejection - prevention & control | Kaplan-Meier Estimate | Kidney Transplantation | Immunoglobulin G - administration & dosage | Opportunistic Infections | Sirolimus - administration & dosage | Mycophenolic Acid - analogs & derivatives | Antibodies, Monoclonal - administration & dosage | Cyclosporine - administration & dosage | Immunosuppressive Agents - adverse effects | Aged | Adrenal Cortex Hormones - administration & dosage | Transplantation | Corticosteroids | Kidneys | Research | Health aspects | Immunosuppressive agents | Medical research | Immunology | Inhibitor drugs | Transplants & implants | Toxicity | Inhibidors enzimàtics | Posologia | Ús terapèutic | Corticosteroides | Rebuig (Biologia) | Posology | Therapeutic use | Immunosupressive agents | Graft rejection | Trasplantament renal | Enzyme inhibitors | Adrenocortical hormones | Immunosupressors | Kidney transplantation | Tacrolimus: administration & dosage | Medical and Health Sciences | Graft Rejection: prevention & control | Immunoglobulin G: administration & dosage | Medicin och hälsovetenskap | Mycophenolic Acid: administration & dosage | Antibodies | Klinisk medicin | Monoclonal: administration & dosage | Prednisone: administration & dosage | Adrenal Cortex Hormones: administration & dosage | Immunosuppressive Agents: administration & dosage | Mycophenolic Acid: analogs & derivatives | Sirolimus: administration & dosage | Cyclosporine: administration & dosage | Calcineurin: antagonists & inhibitors | Diabetes Mellitus: etiology | Urologi och njurmedicin | Sirolimus: adverse effects | Adrenal Cortex Hormones: therapeutic use | Enzyme Inhibitors: administration & dosage | Immunosuppressive Agents: adverse effects | Clinical Medicine | Immunosuppressive Agents: therapeutic use | Urology and Nephrology
Journal Article
Journal of hepatology, ISSN 0168-8278, 2012, Volume 58, Issue 4, pp. 792 - 800
Summary Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other... 
Gastroenterology and Hepatology | Boceprevir | Hepatitis C virus infection | Telaprevir | Pharmacokinetics | Drug interactions | CHRONIC HEPATITIS-C | GASTROENTEROLOGY & HEPATOLOGY | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hepatitis C, Chronic - metabolism | Antiviral Agents - pharmacokinetics | Hypnotics and Sedatives - adverse effects | Humans | Hypnotics and Sedatives - administration & dosage | Drug Interactions | Hypoglycemic Agents - administration & dosage | Drug Therapy, Combination | Immunosuppressive Agents - administration & dosage | Cardiovascular Agents - administration & dosage | Anti-Infective Agents - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Opiate Substitution Treatment - adverse effects | Buprenorphine - administration & dosage | Anti-Infective Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Antiviral Agents - adverse effects | Buprenorphine - adverse effects | Antidepressive Agents - administration & dosage | Immunosuppressive Agents - adverse effects | Methadone - administration & dosage | Methadone - adverse effects | Antidepressive Agents - adverse effects | Cardiovascular Agents - adverse effects | Hypoglycemic Agents - adverse effects | Hepatitis C virus
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 2014, Volume 2014, Issue 10, p. CD006618
Background Ulcerative colitis (UC) is a chronic inflammatory bowel disease. Corticosteroids and 5‐aminosalicylates are the most commonly used therapies.... 
Colitis, Ulcerative | Mesalamine | Immunosuppressive Agents | Administration, Oral | Gastroenterology & hepatology | Induction Chemotherapy | Ulcerative colitis: induction of remission | Randomized Controlled Trials as Topic | Inflammatory bowel disease | Anti‐Inflammatory Agents | Methotrexate | Medicine General & Introductory Medical Sciences | ULCERATIVE COLITIS ‐ INDUCTION OF REMISSION | Mercaptopurine | Immunosuppressive Agents [administration & dosage; adverse effects] | 6-Mercaptopurine [administration & dosage] | Methotrexate [administration & dosage; adverse effects] | CROHNS-DISEASE | EFFICACY | Induction Chemotherapy [methods] | Humans | AZATHIOPRINE | NATIONWIDE RETROSPECTIVE COHORT | RANDOMIZED CONTROLLED-TRIAL | MEDICINE, GENERAL & INTERNAL | INFLAMMATORY-BOWEL-DISEASE | THERAPY | Anti-Inflammatory Agents [administration & dosage; adverse effects] | PHARMACOKINETICS | Colitis, Ulcerative [drug therapy] | ORAL METHOTREXATE | Mesalamine [administration & dosage] | INFLIXIMAB | Induction Chemotherapy - methods | Mercaptopurine - administration & dosage | Methotrexate - adverse effects | Anti-Inflammatory Agents - adverse effects | Anti-Inflammatory Agents - administration & dosage | Immunosuppressive Agents - adverse effects | Methotrexate - administration & dosage | Colitis, Ulcerative - drug therapy | Immunosuppressive Agents - administration & dosage | Mesalamine - administration & dosage
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2008, Volume 134, Issue 7, pp. 1861 - 1868
Background & Aims: The benefit to risk ratio of concomitant immunosuppressives with scheduled infliximab (IFX) maintenance therapy for Crohn's disease is an... 
Gastroenterology and Hepatology | RHEUMATOID-ARTHRITIS | ANTIBODIES | MULTICENTER | INFLAMMATORY-BOWEL-DISEASE | THERAPY | SERUM INFLIXIMAB | LYMPHOMA | RISK | INDUCTION | GASTROENTEROLOGY & HEPATOLOGY | SHORT-TERM | Azathioprine - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gastrointestinal Agents - administration & dosage | Crohn Disease - metabolism | Male | Intestinal Mucosa - drug effects | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Infliximab | Adult | Anti-Inflammatory Agents - administration & dosage | Anti-Inflammatory Agents - pharmacokinetics | Female | Drug Therapy, Combination | France | Gastrointestinal Agents - pharmacokinetics | Immunosuppressive Agents - administration & dosage | Drug Administration Schedule | Mercaptopurine - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Belgium | Antibodies, Monoclonal - administration & dosage | Crohn Disease - pathology | Crohn Disease - drug therapy | Methotrexate - administration & dosage | Gastrointestinal Agents - adverse effects | Infusions, Intravenous | Intestinal Mucosa - pathology | Clinical trials | Crohn's disease | C-reactive protein | Tumor necrosis factor | Immunotherapy | Life Sciences | Human health and pathology | Hépatology and Gastroenterology
Journal Article
JAMA dermatology (Chicago, Ill.), ISSN 2168-6068, 09/2017, Volume 153, Issue 11, pp. 1147 - 1157
Journal Article
Journal Article
Biology of blood and marrow transplantation, ISSN 1083-8791, 2013, Volume 19, Issue 1, pp. 117 - 122
Abstract Fifty patients with high-risk hematologic malignancies, underwent an unmanipulated haploidentical bone marrow transplantation (BMT), followed by... 
Hematology, Oncology and Palliative Medicine | Haploidentical transplantations | Acute leukemia | HLA | Posttransplantation cyclophosphamide | Allogeneic stem cell transplant | MORTALITY | IMMUNOLOGY | RECIPIENTS | VERSUS-HOST-DISEASE | TRANSPLANTATION | REDUCED-INTENSITY | ACUTE-LEUKEMIA | HIGH-RISK | HAPLOTYPE | OUTCOMES | STEM-CELL TRANSPLANTATION | HEMATOLOGY | BLOOD | Hematologic Neoplasms - therapy | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Follow-Up Studies | Myeloablative Agonists - adverse effects | Thiotepa - administration & dosage | Hematologic Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Busulfan - administration & dosage | Cyclophosphamide - adverse effects | Transplantation, Homologous | Graft vs Host Disease - mortality | Antineoplastic Agents - adverse effects | Bone Marrow Transplantation | Adult | Female | Retrospective Studies | Graft vs Host Disease - etiology | Immunosuppressive Agents - administration & dosage | Acute Disease | Busulfan - adverse effects | Vidarabine - adverse effects | Survival Rate | Vidarabine - analogs & derivatives | Disease-Free Survival | Adolescent | Myeloablative Agonists - administration & dosage | Graft vs Host Disease - prevention & control | Immunosuppressive Agents - adverse effects | Aged | Vidarabine - administration & dosage | Transplantation Conditioning | Chronic Disease | Thiotepa - adverse effects | Antimitotic agents | Pneumonia | Cyclophosphamide | Bacterial pneumonia | Mortality | Bone marrow | Transplantation | Antineoplastic agents | Cancer
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2013, Volume 60, Issue 4, pp. 872 - 884
... and in vivo expression of both CYP3A4/5 and P-gp vary substantially between individuals [1–6] . As a result, administration of a drug that is a CYP3A or P-gp substrate... 
Gastroenterology and Hepatology | Immunosuppression | Antiviral therapy | Hepatitis C | Cytochrome P450 | Calcineurin inhibitors | PHARMACOKINETIC INTERACTION | PEGYLATED INTERFERON ALPHA-2A | PROTEASE INHIBITOR BOCEPREVIR | SUSTAINED VIROLOGICAL RESPONSE | GENOTYPE 1 | HEPATITIS-C VIRUS | CAUSALITY ASSESSMENT | SIMEPREVIR TMC435 | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | Hepatitis C, Chronic - metabolism | Liver Transplantation - adverse effects | Humans | Immunosuppressive Agents - pharmacokinetics | Oligopeptides - adverse effects | TOR Serine-Threonine Kinases - antagonists & inhibitors | Drug Interactions | Anti-Bacterial Agents - adverse effects | Chemical and Drug Induced Liver Injury - etiology | Immunosuppressive Agents - administration & dosage | Tacrolimus - administration & dosage | Proline - administration & dosage | Proline - analogs & derivatives | Administration, Oral | Calcineurin Inhibitors - administration & dosage | Risk Factors | Hepatitis C, Chronic - surgery | Tacrolimus - pharmacokinetics | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Chemical and Drug Induced Liver Injury - diagnosis | Antiviral Agents - adverse effects | Proline - adverse effects | Oligopeptides - administration & dosage | Anti-Bacterial Agents - administration & dosage | Complications and side effects | Liver diseases | Protease inhibitors | Proteases | Liver | Drug interactions | Organ transplant recipients | Transplantation | Hepatitis C virus | Immunosuppressive agents | Index Medicus
Journal Article
Leukemia, ISSN 0887-6924, 12/2008, Volume 22, Issue 12, pp. 2247 - 2256
This phase 2 study aimed to determine the efficacy and safety of the combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT)... 
MULTIPLE-MYELOMA | SURVIVAL | CELLS | multiple myeloma | RESORPTION | MARROW | melphalan | angiogenesis | MARKERS | PREDNISONE | bone metabolism | SERUM CONCENTRATIONS | thalidomide | ONCOLOGY | DISEASE | RECEPTOR ACTIVATOR | bortezomib | HEMATOLOGY | Neovascularization, Physiologic - drug effects | Recurrence | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Male | Antineoplastic Agents, Alkylating - administration & dosage | Bone Remodeling - drug effects | Bone and Bones - drug effects | Antineoplastic Agents, Hormonal - adverse effects | Multiple Myeloma - drug therapy | Melphalan - adverse effects | Bone and Bones - metabolism | Aged, 80 and over | Adult | Female | Boronic Acids - administration & dosage | Immunosuppressive Agents - administration & dosage | Multiple Myeloma - physiopathology | Biomarkers - metabolism | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Cytokines - metabolism | Antineoplastic Agents, Hormonal - administration & dosage | Survival Rate | Thalidomide - administration & dosage | Multiple Myeloma - metabolism | Melphalan - administration & dosage | Pyrazines - adverse effects | Immunosuppressive Agents - adverse effects | Aged | Antineoplastic Agents, Alkylating - adverse effects | Antimitotic agents | Multiple myeloma | Physiological aspects | Genetic aspects | Dosage and administration | Drug therapy, Combination | Neovascularization | Research | Drug therapy | Antineoplastic agents | Health aspects | Index Medicus
Journal Article
Journal Article